Clinical trial
A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR)…
NCT00364546 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry · Completed
Key facts
| NCT number | NCT00364546 |
|---|---|
| Title | A Study to Evaluate 90-Day Safety of Tapentadol(CG5503) Immediate Release (IR) or Oxycodone Immediate Release in Patients With Chronic Pain |
| Official title | A Randomized, Double-Blind, Active-Control, Parallel-Group, 90-Day Safety Study of CG5503 Immediate Release (IR) or Oxycodone IR in Subjects With Chronic Pain From Low Back Pain or Osteoarthritis of the Hip or Knee |
| Lead sponsor | Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Industry |
| Collaborators | Grünenthal GmbH Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Osteoarthritis, Pain Intensity Assessment, Arthralgia, Sciatica, Low Back Pain |
| Intervention type | Drug |
| Interventions | CG 5503, tapentadol |
| Enrollment | 877 |
| Start date | Jul 1, 2006 |
| Primary completion | Jun 1, 2007 |
| Completion | Jul 1, 2007 |
| First posted | Aug 15, 2006 |
| Last update posted | Jun 9, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: